EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy

Penghao Ji, Bolin An, Zhongming Jie, Liping Wang, Shuwen Qiu, Changhao Ge, Qihui Wu, Jianlin Shi, Minfeng Huo

Materials Today Bio · 2023-02 · 18 · 100515

DOI: 10.1016/j.mtbio.2022.100515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Materials Today Bio, 2023-02. Verfasst von Penghao Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 20007…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Chinese Academy of Sciences, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells predominantly adapt the frequent but less efficient glycolytic process to produce ATPs rather than the highly efficient oxidative phosphorylation pathway. Such a regulated metabolic pattern in cancer cells offers promising therapeutic opportunities to kill tumors by glucose depletion or glycolysis blockade. In addition, to guarantee tumor-specific therapeutic targets, effective tumor-homing, accumulation, and retention strategies toward tumor regions should be elaborately designed. In the present work, genetically engineered tumor-targeting microbes (transgenic microorganism EcM-GDH (Escherichia coli MG1655) expressing exogenous glucose dehydrogenase (GDH) have been constructed to competitively deprive tumors of glucose nutrition for metabolic intervention and starvation therapy. Our results show that the engineered EcM-GDH can effectively deplete glucose and trigger pro-death autophagy and p53-initiated apoptosis in colorectal tumor cells/tissues both in vitro and in vivo. The present design illuminates the promising prospects for genetically engineered microbes in metabolic intervention therapeutics against malignant tumors based on catalytically nutrient deprivation, establishing an attractive probiotic therapeutic strategy with high effectiveness and biocompatibility.

Schlagwörter

Stichwörter der Autor:innen

AutophagyGlucose deprivationMetabolic interventionProgrammable living biomaterialsTumor targeting

Autor:innen und Institutionen

  • Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, PR China.
  • State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease…
  • Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, PR China.
  • Center for Materials Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
  • CAS Key Laboratory of Quantitative Engineering Biology, Materials Synthetic Biology Center, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 5180…
  • School of Physical Science and Technology, Shanghai Tech University, Shanghai, 201210, PR China.

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • Chinese Academy of Sciences
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Chinese Academy of Meteorological Sciences
  • Chinese Academy of Medical Sciences
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Ji, P., An, B., Jie, Z., Wang, L., Qiu, S., Ge, C., Wu, Q., Shi, J., & Huo, M. (2023). Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy. Materials Today Bio, 18, 100515. https://doi.org/10.1016/j.mtbio.2022.100515

Vancouver

Ji P, An B, Jie Z, Wang L, Qiu S, Ge C, et al. Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy. Materials Today Bio. 2023;18:100515. doi:10.1016/j.mtbio.2022.100515

BibTeX
@article{Ji2023,
  author = {Ji, Penghao and An, Bolin and Jie, Zhongming and Wang, Liping and Qiu, Shuwen and Ge, Changhao and Wu, Qihui and Shi, Jianlin and Huo, Minfeng},
  title = {Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy},
  journal = {Materials Today Bio},
  year = {2023},
  volume = {18},
  pages = {100515},
  doi = {10.1016/j.mtbio.2022.100515}
}
Kostenlos starten →